| [1] |
Fraser SDS, Roderick PJ. Kidney disease in the global burden of disease study 2017 [J]. Nat Rev Nephrol, 2019, 15(4): 193-194.
|
| [2] |
Luyckx VA, Al-Aly Z, Bello AK, et al. Sustainable development goals relevant to kidney health: an update on progress [J]. Nat Rev Nephrol, 2021, 17(1): 15-32.
|
| [3] |
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases [J]. Kidney Int, 2021, 100(4S): S1-S276.
|
| [4] |
Bochon B, Kozubska M, Surygala G et al. Mesenchymal stem cells-potential applications in kidney diseases [J]. Int J Mol Sci, 2019, 20(10): 2462.
|
| [5] |
Yun CW, Lee SH. Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute/chronic kidney disease [J]. Int J Mol Sci, 2019, 20(7): 1619.
|
| [6] |
Sears V, Ghosh G. Harnessing mesenchymal stem cell secretome: effect of extracellular matrices on proangiogenic signaling [J]. Biotechnol Bioeng, 2020, 117(4): 1159-1171.
|
| [7] |
Wu J, Huang L, He H, et al. Red cell distribution width to platelet ratio is associated with increasing in-hospital mortality in critically ill patients with acute kidney injury [J]. Dis Markers, 2022, 2022: 4802702.
|
| [8] |
Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J]. Exp Hematol, 2002, 30(1): 42-48.
|
| [9] |
Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli [J]. Blood, 2002, 99(10): 3838-3843.
|
| [10] |
Fazekas B, Griffin MD. Mesenchymal stromal cell-based therapies for acute kidney injury: progress in the last decade [J]. Kidney Int, 2020, 97(6): 1130-1140.
|
| [11] |
Hu CD, Kosaka Y, Marcus P, et al. Differential immunomodulatory effects of human bone marrow-derived mesenchymal stromal cells on natural killer cells [J]. Stem Cells Dev, 2019, 28(14): 933-943.
|
| [12] |
MarkovA, Thangavelu L, Aravindhan S, et al. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders [J]. Stem Cell Res Ther, 2021, 12(1): 192.
|
| [13] |
Lopez-Garcia L, Castro-Manrreza ME. TNF-alpha and IFN-gamma participate in improving the immunoregulatory capacity of mesenchymal stem/stromal cells: importance of cell-cell contact and extracellular vesicles [J]. Int J Mol Sci, 2021, 22(17): 9531.
|
| [14] |
Fan L, Hu C, Chen J, et al. Interaction between mesenchymal stem cells and b-cells [J]. Int J Mol Sci, 2016, 17(5): 650.
|
| [15] |
Yuan Y, Li L, Zhu L, et al. Mesenchymal stem cells elicit macrophages into M2 phenotype via improving transcription factor EB-mediated autophagy to alleviate diabetic nephropathy [J]. Stem cells, 2020, 38(5): 639-652.
|
| [16] |
Chen J, Park HC, Addabbo F, et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair [J]. Kidney Int, 2008, 74(7): 879-889.
|
| [17] |
Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells [J]. Cytokine Growth Factor Rev, 2009, 20(5-6): 419-427.
|
| [18] |
Pleniceanu O, Harari-Steinberg O, Omer D, et al. Successful introduction of human renovascular units into the mammalian kidney [J]. J Am Soc Nephrol, 2020, 31(12): 2757-2772.
|
| [19] |
Chen F, Chen N, Xia C, et al. Mesenchymal stem cell therapy in kidney diseases: potential and challenges [J]. Cell Transplant, 2023, 32: 9636897231164251.
|
| [20] |
Sano T, Nakajima T, Senda KA, et al. Image-based crosstalk analysis of cell-cell interactions during sprouting angiogenesis using blood-vessel-on-a-chip [J]. Stem Cell Res Ther, 2022, 13(1): 532.
|
| [21] |
Liang W, Chen X, Zhang S, et al. Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines [J]. Cell Mol Biol Lett, 2021, 26(1): 3.
|
| [22] |
Katsuno T, Ozaki T, Saka Y, et al. Low serum cultured adipose tissue-derived stromal cells ameliorate acute kidney injury in rats [J]. Cell Transplant, 2013, 22(2): 287-297.
|
| [23] |
Li L, Cheng D, An X, et al. Mesenchymal stem cells transplantation attenuates hyperuricemic nephropathy in rats [J]. Int Immunopharmacol, 2021, 99: 108000.
|
| [24] |
Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury [J]. Am J Physiol Renal Physiol, 2007, 292(5): F1626-F1635.
|
| [25] |
Ni W, Fang Y, Xie L, et al. Adipose- derived mesenchymal stem cells transplantation alleviates renal injury in streptozotocin-induced diabetic nephropathy [J]. J Histochem Cytochem, 2015, 63(11): 842-853.
|
| [26] |
Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis [J]. Nat Rev Nephrol, 2016, 12(6): 325-338.
|
| [27] |
Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis [J]. Stem Cell Res Ther, 2020, 11(1): 336.
|
| [28] |
Ishiuchi N, Nakashima A, Doi S, et al. Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats [J]. Stem Cell Res Ther, 2020, 11(1): 130.
|
| [29] |
Ishiuchi N, Nakashima A, Doi S, et al. Serum-free medium and hypoxic preconditioning synergistically enhance the therapeutic effects of mesenchymal stem cells on experimental renal fibrosis [J]. Stem Cell Res Ther, 2021, 12(1): 472.
|
| [30] |
Wang B, Kim K, Tian M, et al. Engineered bone marrow stem cell-sheets alleviate renal damage in a rat chronic glomerulonephritis model [J]. Int J Mol Sci, 2023, 24(4): 3711.
|
| [31] |
Carlstrom M. Nitric oxide signalling in kidney regulation and cardiometabolic health [J]. Nat Rev Nephrol, 2021, 17(9): 575-590.
|
| [32] |
Braga PC, Alves MG, Rodrigues AS, et al. Mitochondrial pathophysiology on chronic kidney disease [J]. Int J Mol Sci, 2022, 23(3): 1776.
|
| [33] |
Stavely R, Nurgali K. The emerging antioxidant paradigm of mesenchymal stem cell therapy [J]. Stem Cells Transl Med, 2020, 9(9): 985-1006.
|
| [34] |
Liu B, Ding FX, Liu Y, et al. Human umbilical cord-derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction [J]. Nephrology (Carlton), 2018, 23(8): 728-736.
|
| [35] |
Savio-Silva C, Soinski-Sousa PE, Simplicio-Filho A, et al. Therapeutic potential of mesenchymal stem cells in a pre-Clinical model of diabetic kidney disease and obesity [J]. Int J Mol Sci, 2021, 22(4): 1546.
|
| [36] |
Hafazeh L, Changizi-Ashtiyani S, Ghasemi F, et al. Stem cell therapy ameliorates ischemia-reperfusion induced kidney injury after 24 hours reperfusion [J]. Iran J Kidney Dis, 2019, 13(6): 380-388.
|
| [37] |
Tang C, Livingston MJ, Liu Z, et al. Autophagy in kidney homeostasis and disease [J]. Nat Rev Nephrol, 2020, 16(9): 489-508.
|
| [38] |
刘华锋，杨俊伟. 细胞自噬与肾脏疾病研究中国专家共识[J]. 中国病理生理杂志，2021, 37(10): 1876-1887.
|
| [39] |
Jia H, Yan Y, Liang Z, et al. Autophagy: a new treatment strategy for MSC-based therapy in acute kidney injury (Review) [J]. Mol Med Rep, 2018, 17(3): 3439-3447.
|
| [40] |
Ebrahim N, Ahmed IA, Hussien NI, et al. Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway [J]. Cells, 2018, 7(12): 226.
|
| [41] |
Huang J, Kong Y, Xie C, et al. Stem/progenitor cell in kidney: characteristics, homing, coordination, and maintenance [J]. Stem Cell Res Ther, 2021, 12(1): 197.
|
| [42] |
Birtwistle L, Chen XM, Pollock C. Mesenchymal stem cell-derived extracellular vesicles to the rescue of renal injury [J]. Int J Mol Sci, 2021, 22(12): 6596.
|
| [43] |
Harrell CR, Jovicic N, Djonov V, et al. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases [J]. Cells, 2019, 8(12): 1605.
|
| [44] |
Liu H, Chen Y, Yin G, et al. Therapeutic prospects of microRNAs carried by mesenchymal stem cells-derived extracellular vesicles in autoimmune diseases [J]. Life Sci, 2021, 277: 119458.
|
| [45] |
Grange C, Skovronova R, Marabese F, et al. Stem cell-derived extracellular vesicles and kidney regeneration [J]. Cells, 2019, 8(10): 1240.
|
| [46] |
Eirin A, Lerman LO. Mesenchymal stem/stromal cell-derived extracellular vesicles for chronic kidney disease: are we there yet? [J]. Hypertension, 2021, 78(2): 261-269.
|
| [47] |
Lu Y, Wang L, Zhang M, et al. Mesenchymal stem cell-derived small extracellular vesicles: a novel approach for kidney disease treatment [J]. Int J Nanomedicine, 2022, 17: 3603-3618.
|
| [48] |
Ito T, Suzuki A, Okabe M, et al. Application of bone marrow-derived stem cells in experimental nephrology [J]. Exp Nephrol, 2001, 9(6): 444-450.
|
| [49] |
Wong CY, Cheong SK, Mok PL, et al. Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model [J]. Pathology, 2008, 40(1): 52-57.
|
| [50] |
Masuya M, Drake CJ, Fleming PA, et al. Hematopoietic origin of glomerular mesangial cells [J]. Blood, 2003, 101(6): 2215-2218.
|
| [51] |
Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure [J]. J Am Soc Nephrol, 2004, 15(7): 1794-1804.
|
| [52] |
Herrera MB, Bussolati B, Bruno S, et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury [J]. Int J Mol Med, 2004, 14(6): 1035-1041.
|
| [53] |
Lin F, Cordes K, Li L, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice [J]. J Am Soc Nephrol, 2003, 14(5): 1188-1199.
|
| [54] |
Yokoo T, Ohashi T, Shen JS, et al. Human mesenchymal stem cells in rodent whole-embryo culture are reprogrammed to contribute to kidney tissues [J]. Proc Natl Acad Sci USA, 2005, 102(9): 3296-3300.
|
| [55] |
Vassilopoulos G, Russell DW. Cell fusion: an alternative to stem cell plasticity and its therapeutic implications [J]. Curr Opin Genet Dev, 2003, 13(5): 480-485.
|
| [56] |
Brukman NG, Uygur B, Podbilewicz B, et al. How cells fuse [J]. J Cell Biol, 2019, 218(5): 1436-1451.
|
| [57] |
Held PK, Al-Dhalimy M, Willenbring H, et al. In vivo genetic selection of renal proximal tubules [J]. Mol Ther, 2006, 13(1): 49-58.
|
| [58] |
Swaminathan M, Stafford-Smith M, Chertow GM, et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery [J]. J Am Soc Nephrol, 2018, 29(1): 260-267.
|
| [59] |
Makhlough A, Shekarchian S, Moghadasali R, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: a safety study with 18 months of follow-up [J]. Cytotherapy, 2018, 20(5): 660-669.
|
| [60] |
Chun S, Choi CB, Kim MS, et al. Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans [J]. Lupus, 2022, 31(10): 1245-1253.
|
| [61] |
Liang J, Zhang H, Kong W, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study [J]. Stem Cell Res Ther, 2018, 9(1): 312.
|
| [62] |
Makhlough A, Shekarchian S, Moghadasali R, et al. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients [J]. Stem Cell Res Ther, 2017, 8(1): 116.
|
| [63] |
Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study [J]. Arthritis Res Ther, 2014, 16(2): R79.
|
| [64] |
Abumoawad A, Saad A, Ferguson CM, et al. In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure [J]. Kidney Int, 2020, 97(4): 793-804.
|
| [65] |
Deng D, Zhang P, Guo Y, et al. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis [J]. Ann Rheum Dis, 2017, 76(8): 1436-1439.
|
| [66] |
Naeem A, Gupta N, Naeem U, et al. A comparison of isolation and culture protocols for human amniotic mesenchymal stem cells [J]. Cell Cycle, 2022, 21(15): 1543-1556.
|
| [67] |
Camilleri ET, Gustafson MP, Dudakovic A, et al. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production [J]. Stem Cell Res Ther, 2016, 7(1): 107.
|